CRL · 8-K · 20261109PR017127

Clinical Bioanalysis Client Continuity

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-09 · Importance 23 · Surprise 24

Charles River says clients increasingly seek continuity from laboratory testing partners as programs move from preclinical to clinical development, with preclinical bioanalysis data informing early clinical decisions. Approximately 15% of Charles River’s bioanalysis revenue currently comes from clinical-phase testing, while the majority of Frontage’s 2025 bioanalysis revenue was generated during clinical development. The expanded clinical bioanalysis capabilities are intended to support clients through late-stage clinical diagnostic testing and strengthen retention and share of wallet across longer-duration programs.

Key facts

• The acquisition is expected to expand Charles River’s clinical bioanalysis capabilities and scale, including support for late-stage clinical diagnostic testing. source
• Charles River expects a more balanced and integrated bioanalysis portfolio to strengthen client relationships, increase share of wallet, and improve client retention throughout longer-duration clinical programs. source
• Approximately 15% of Charles River’s bioanalysis revenue is currently generated from clinical-phase testing. source
• In 2025, the majority of Frontage’s bioanalysis revenue was generated during clinical development. source
• Charles River said clients increasingly seek continuity from laboratory testing partners as programs advance from preclinical to clinical development, because preclinical bioanalysis data helps guide early clinical decisions. source